⚙
AI-generated summary
by qwen3.7-flash, 2026-09-23
ⓘ
This meta-analysis of 45 randomized controlled trials found that vitamin D supplementation modestly reduced LDL cholesterol, systolic blood pressure, fasting glucose, and HbA1c, with effects modified by age and baseline vitamin D levels.
⚙
AI-generated deep summary
by qwen3.7-flash, 2026-09-23
· read from full text
ⓘ
This systematic review and meta-analysis evaluated the impact of vitamin D supplementation on cardiometabolic risk factors by analyzing data from 45 randomized controlled trials involving over 14,000 participants. The authors found that supplementation significantly reduced low-density lipoprotein cholesterol, systolic blood pressure, fasting blood glucose, and hemoglobin A1c compared to placebo, with effects varying based on age and baseline vitamin D levels. The study notes that while these reductions are statistically significant, their clinical significance remains uncertain and further research is required. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.
Abstract
BACKGROUND AND OBJECTIVES: Vitamin D has been proposed to influence several cardiometabolic risk factors; however, evidence from randomized controlled trials (RCTs) and recent meta-analyses remains inconsistent regarding the magnitude of these effects. This meta-analysis evaluated the effects of vitamin D supplementation on lipid profile, blood pressure, and glycaemic parameters, and explored whether age and baseline serum vitamin D concentrations modified these associations.
METHODS AND STUDY DESIGN: A systematic review and meta-analysis of RCTs was conducted to compare oral vitamin D supplementation with placebo in adults. PubMed, the Cochrane Library, and ClinicalTrials.gov were searched systematically. Risk of bias was as-sessed using the Cochrane risk-of-bias tool. Pooled effect sizes with 95% confidence intervals (CIs) were estimated using random-effects models.
RESULTS: A total of 14,051 abstracts were identified, and 45 RCTs were included in the final analysis. Vitamin D supplementation significantly reduced low-density lipoprotein cho-lesterol (LDL-C) by 0.136 mmol/L (95% CI: -0.215, -0.056), systolic blood pressure (SBP) by 2.79 mm Hg (95% CI: -4.65, -0.94), fasting blood glucose (FBG) by 0.11 mmol/L (95% CI: -0.19, -0.04), and hemoglobin A1c (HbA1c) by 0.164% (95% CI: -0.32, -0.01) compared with placebo. Subgroup analyses showed reductions in SBP and LDL-C among participants aged ≥55 years, whereas FBG was reduced in those aged <55 years. While favorable effects on FBG and HbA1c were observed with a baseline blood level of vitamin D of less than 50 nmol/L.
CONCLUSIONS: Vitamin D supplementation may modestly improve selected cardiomet-abolic risk factors. Age and baseline vitamin D status may influence these effects, although their clinical sig-nificance remains uncertain. Further well-designed RCTs are needed.
Full text
1,853 characters
· extracted from
oa-doi-fallback
· click to expand
- 期刊
Background and Objectives: Vitamin D has been proposed to influence several cardiometabolic risk factors; however, evidence from randomized controlled trials (RCTs) and recent meta-analyses remains inconsistent regarding the magnitude of these effects. This meta-analysis evaluated the effects of vitamin D supplementation on lipid profile, blood pressure, and glycaemic parameters, and explored whether age and baseline serum vitamin D concentrations modified these associations. Methods and Study Design: A systematic review and meta-analysis of RCTs was conducted to compare oral vitamin D supplementation with placebo in adults. PubMed, the Cochrane Library, and ClinicalTrials.gov were searched systematically. Risk of bias was assessed using the Cochrane risk-of-bias tool. Pooled effect sizes with 95% confidence intervals (CIs) were estimated using random-effects models. Results: A total of 14,051 abstracts were identified, and 45 RCTs were included in the final analysis. Vitamin D supplementation significantly reduced low-density lipoprotein cholesterol (LDL-C) by 0.136 mmol/L (95% CI: -0.215, -0.056), systolic blood pressure (SBP) by 2.79 mm Hg (95% CI: -4.65, -0.94), fasting blood glucose (FBG) by 0.11 mmol/L (95% CI: -0.19, -0.04), and hemoglobin A1c (HbA1c) by 0.164% (95% CI: -0.32, -0.01) compared with placebo. Subgroup analyses showed reductions in SBP and LDL-C among participants aged ≥55 years, whereas FBG was reduced in those aged <55 years. While favorable effects on FBG and HbA1c were observed with a baseline blood level of vitamin D of less than 50 nmol/L. Conclusions: Vitamin D supplementation may modestly improve selected cardiometabolic risk factors. Age and baseline vitamin D status may influence these effects, although their clinical significance remains uncertain. Further well-designed RCTs are needed.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.